Glycine is an amino acid and one of the main inhibitory neurotransmitters in the brain. Glycine normalizes and activates protective inhibition processes in the central nervous system, reduces psycho-emotional stress, and increases mental performance. Glycine has glycine- and GABA-ergic, alpha1-adrenergic blocking effects, regulates the activity of glutamate (NMDA) receptors. The drug has the following properties:

reduces psycho-emotional stress, aggressiveness, conflict, increases social adaptation;
improves mood;
makes it easier to fall asleep and normalizes sleep;
increases mental performance;
reduces vegetative-vascular disorders (including during menopause);
reduces the severity of brain disorders in ischemic stroke and traumatic brain injury;
reduces the toxic effect of alcohol and other drugs that depress the function of the central nervous system. Indications for use:

reduced mental performance.
stressful situations - psycho-emotional stress (during exams, in conflict situations, etc.);
deviant (deviating from the norm) forms of behavior of children and adolescents;
various functional and organic diseases of the nervous system, accompanied by increased excitability, emotional instability, decreased mental performance, memory and sleep disturbances: neuroses, neurosis-like conditions and vegetative-vascular dystonia, stress nervous disorders, consequences of neuroinfections and traumatic brain injury, perinatal and other forms encephalopathies (including alcoholic origin);
ischemic stroke. Directions for use and dosage: Glycine is applied sublingually. children over three years old - 1 tablet (100 mg), children under three years old - 0.5 tablets (50 mg) adolescents and adults with psycho-emotional stress, stress nervous disorders, decreased memory, attention, mental performance, mental retardation, for deviant forms of behavior: 2-3 times a day for 14-30 days. used as a means of increasing mental performance and reducing psycho-emotional stress during the period of remission in cases of encephalopathy, organic lesions of the central and peripheral nervous system: 1 tablet 2-3 times a day for 14-30 days. If necessary, courses are repeated 4-6 times a year.